Literature DB >> 26279685

The evolving role of the pathologist in the management of lung cancer.

Adi F Gazdar1.   

Abstract

Major advances in pathology, molecular biology, patient diagnosis and care, as well as the advent of personalized therapy, have resulted in a greatly increased role for the pathologist, who has emerged as a key member of the lung cancer management team. A new multidisciplinary, clinically relevant classification of pulmonary adenocarcinoma has resulted in a paradigm shift in how we view and practice lung cancer pathology. In the future, the role of the pathologist will continue to grow and become fully integrated with clinical care.

Entities:  

Year:  2012        PMID: 26279685      PMCID: PMC4535720          DOI: 10.2217/lmt.12.43

Source DB:  PubMed          Journal:  Lung Cancer Manag        ISSN: 1758-1966


  58 in total

1.  SnapShot: non-small cell lung cancer.

Authors:  Rebecca S Heist; Jeffrey A Engelman
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

2.  Multifocal lung cancers--clonality vs field cancerization and does it matter?

Authors:  Adi F Gazdar; John D Minna
Journal:  J Natl Cancer Inst       Date:  2009-04-07       Impact factor: 13.506

Review 3.  Clinical cancer genomics: how soon is now?

Authors:  Barry S Taylor; Marc Ladanyi
Journal:  J Pathol       Date:  2010-10-28       Impact factor: 7.996

Review 4.  Bevacizumab in non-small-cell lung cancer: a review.

Authors:  David Planchard
Journal:  Expert Rev Anticancer Ther       Date:  2011-08       Impact factor: 4.512

5.  Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.

Authors:  Natasha Rekhtman; Suzanne M Brandt; Carlie S Sigel; Maria A Friedlander; Gregory J Riely; William D Travis; Maureen F Zakowski; Andre L Moreira
Journal:  J Thorac Oncol       Date:  2011-03       Impact factor: 15.609

6.  Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens.

Authors:  Natasha Rekhtman; Daphne C Ang; Camelia S Sima; William D Travis; Andre L Moreira
Journal:  Mod Pathol       Date:  2011-05-27       Impact factor: 7.842

Review 7.  Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing.

Authors:  William D Travis; Natasha Rekhtman
Journal:  Semin Respir Crit Care Med       Date:  2011-04-15       Impact factor: 3.119

8.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

9.  Personalized medicine and inhibition of EGFR signaling in lung cancer.

Authors:  Adi F Gazdar
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

10.  Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations.

Authors:  Richard A Hubner; Richard D Riley; Lucinda J Billingham; Sanjay Popat
Journal:  PLoS One       Date:  2011-10-14       Impact factor: 3.240

View more
  1 in total

1.  Genome-wide copy number variation pattern analysis and a classification signature for non-small cell lung cancer.

Authors:  Zhe-Wei Qiu; Jia-Hao Bi; Adi F Gazdar; Kai Song
Journal:  Genes Chromosomes Cancer       Date:  2017-05-04       Impact factor: 5.006

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.